Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer

Purpose: Genetic analysis of bladder cancer has revealed a number of frequently altered genes, including frequent alterations of the telomerase (TERT) gene promoter, although few altered genes have been functionally evaluated. Our objective is to characterize alterations observed by exome sequencing and sequencing of the TERT promoter, and to examine the functional relevance of histone lysine (K)–specific demethylase 6A (KDM6A/UTX), a frequently mutated histone demethylase, in bladder cancer. Experimental Design: We analyzed bladder cancer samples from 54 U.S. patients by exome and targeted sequencing and confirmed somatic variants using normal tissue from the same patient. We examined the biologic function of KDM6A using in vivo and in vitro assays. Results: We observed frequent somatic alterations in BRCA1 associated protein-1 (BAP1) in 15% of tumors, including deleterious alterations to the deubiquitinase active site and the nuclear localization signal. BAP1 mutations contribute to a high frequency of tumors with breast cancer (BRCA) DNA repair pathway alterations and were significantly associated with papillary histologic features in tumors. BAP1 and KDM6A mutations significantly co-occurred in tumors. Somatic variants altering the TERT promoter were found in 69% of tumors but were not correlated with alterations in other bladder cancer genes. We examined the function of KDM6A, altered in 24% of tumors, and show depletion in human bladder cancer cells, enhanced in vitro proliferation, in vivo tumor growth, and cell migration. Conclusions: This study is the first to identify frequent BAP1 and BRCA pathway alterations in bladder cancer, show TERT promoter alterations are independent of other bladder cancer gene alterations, and show KDM6A loss is a driver of the bladder cancer phenotype. Clin Cancer Res; 20(18); 4935–48. ©2014 AACR.

[1]  Garrett M. Dancik,et al.  A Cell of Origin Gene Signature Indicates Human Bladder Cancer Has Distinct Cellular Progenitors , 2014, Stem cells.

[2]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[3]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[4]  M. Rubin,et al.  Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.

[5]  Karin M. Fredrikson,et al.  Somatic Alterations Contributing to Metastasis of a Castration‐Resistant Prostate Cancer , 2013, Human mutation.

[6]  J. Brugarolas,et al.  Cooperation and antagonism among cancer genes: the renal cancer paradigm. , 2013, Cancer research.

[7]  Feng Tian,et al.  Expression of CHD1L in bladder cancer and its influence on prognosis and survival , 2013, Tumor Biology.

[8]  N. Grishin,et al.  A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.

[9]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[10]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[11]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[12]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[13]  J. Chesney,et al.  Molecular Pathways: Regulation of Metabolism by RB , 2012, Clinical Cancer Research.

[14]  C. Taylor,et al.  Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis , 2012, Clinical Cancer Research.

[15]  Shu-Dong Zhang,et al.  Differential TERT promoter methylation and response to 5‐aza‐2′‐deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death , 2012, Genes, chromosomes & cancer.

[16]  P. Winyard,et al.  CHD1L: a new candidate gene for congenital anomalies of the kidneys and urinary tract (CAKUT). , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[18]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[19]  G. Phillips,et al.  Structural characterization of human Uch37 , 2012, Proteins.

[20]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[21]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[22]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[23]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[24]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[25]  S. Sugano,et al.  The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase. , 2010, Biochemical and biophysical research communications.

[26]  Christopher C. Ebmeier,et al.  Activator-Mediator binding regulates Mediator-cofactor interactions , 2010, Proceedings of the National Academy of Sciences.

[27]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[28]  X. Wang,et al.  CSPG4 in cancer: multiple roles. , 2010, Current molecular medicine.

[29]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Wilm,et al.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB , 2010, Nature.

[31]  R. Marschalek.  Mixed lineage leukemia: roles in human malignancies and potential therapy , 2010, The FEBS journal.

[32]  Erwin G. Van Meir,et al.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. , 2008, Cancer research.

[33]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[34]  Jun Yokota,et al.  Frequent BRG1/SMARCA4–inactivating mutations in human lung cancer cell lines , 2008, Human mutation.

[35]  Min Gyu Lee,et al.  Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.

[36]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[37]  C. Croce,et al.  Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth , 2006, Molecular and Cellular Biology.

[38]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[39]  Yong-Yeon Cho,et al.  Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. , 2005, Cancer research.

[40]  M. Knowles,et al.  Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.

[41]  J. Benhattar,et al.  Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. , 2003, Experimental cell research.

[42]  D. Theodorescu,et al.  Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer , 2000, Genes, chromosomes & cancer.

[43]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[44]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[45]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[46]  F. Collins,et al.  Characterization of the CHD family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Cordon-Cardo,et al.  p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns , 1994, International journal of cancer.

[48]  H. Thiesen,et al.  Target Detection Assay (TDA): a versatile procedure to determine DNA binding sites as demonstrated on SP1 protein. , 1990, Nucleic acids research.

[49]  Williams Rd.  Human urologic cancer cell lines. , 1980 .

[50]  R. Williams.  Human urologic cancer cell lines. , 1980, Investigative urology.

[51]  R. F. McGregor,et al.  Urinary amino acid excretion: comparison of normal individuals and patients with bladder cancer. , 1977, Urology.

[52]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .